| Elizabethtown Nursing And Rehabilitation | |
| 141 Heisey Avenue, Elizabethtown, Pennsylvania 17022 | |
| (717) 367-1831 | |
| Name | Elizabethtown Nursing And Rehabilitation |
|---|---|
| Location | 141 Heisey Avenue, Elizabethtown, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 45 |
| Occupancy Rate | 95.33% |
| Medicare ID (CCN) | 395844 |
| Legal Business Name | Elizabethtown Opco Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1346628245 |
| Organization Name | RHEEMS OPERATOR, LLC |
| Doing Business As | ELIZABETHTOWN NURSING AND REHABILITATION CENTER |
| Address | 141 Heisey Ave, Elizabethtown, PA 17022 |
| Phone Number | 717-367-1831 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| NPI Number | 1396449831 |
| Organization Name | ET 141 OPERATIONS LLC |
| Address | 141 Heisey Ave, Elizabethtown, PA 17022 |
| Phone Number | 973-250-7500 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| NPI Number | 1740705805 |
| Organization Name | ETOWN OPERATOR LLC |
| Doing Business As | ELIZABETHTOWN HEALTHCARE AND REHAB CENTER |
| Address | 141 Heisey Ave, Elizabethtown, PA 17022 |
| Phone Number | 717-367-1831 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| NPI Number | 1851990675 |
| Organization Name | ELIZABETHTOWN OPCO LLC |
| Address | 141 Heisey Avenue, Elizabethtown, PA 17022 |
| Phone Number | 717-367-1831 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| NPI Number | 1891810826 |
| Organization Name | RHEEMS NURSING AND REHABILITATION CENTER, LLC |
| Address | 141 Heisey Ave, Elizabethtown, PA 17022 |
| Phone Number | 717-367-1831 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.18 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.89 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 77.14 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.17 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 24.22 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.38 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 70.07 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.17 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 26.27 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.74 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.44 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.96 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 90.98 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.38 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 44.79 | 82.93 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
A new study by an international team of researchers and published on the preprint server medRxiv* in July 2020 describes a model to estimate the actual undercounting of COVID-19 cases and the global prevalence.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
"We are all in this together" became a rallying cry during the COVID-19 pandemic in the United States, although a significant portion of the population is not "all in" when it comes to getting vaccinated.
› Verified 2 days ago
Emerald Rehab And Healthcare Center Location: 320 South Market Street, Elizabethtown, Pennsylvania 17022 Phone: (717) 367-1377 | |
Masonic Village At Elizabethtown Location: One Masonic Drive, Elizabethtown, Pennsylvania 17022 Phone: (717) 367-1121 | |
Elizabethtown Nursing And Rehabilitation Location: 141 Heisey Avenue, Elizabethtown, Pennsylvania 17022 Phone: (717) 367-1831 |